EMBC Stock Analysis: Embecta | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 195m USD | 12M Return: -68.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.03M
EPS Trend: -22.7%
Qual. Beats: -1
Rev. Trend: -82.7%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Embecta Corp. (NASDAQ: EMBC) is a U.S.-based medical device company focused exclusively on diabetes care, offering pen needles, syringes, safety injection devices, and supporting digital applications for diabetes management. The company was spun off from Becton, Dickinson and Company (BD) in April 2022, inheriting BDs former Diabetes Care business, and is headquartered in Parsippany, New Jersey. Embecta primarily distributes its products through wholesalers and distributors, serving both the U.S. and international markets.
Operating within the GICS Health Care Supplies sub-industry, Embecta is positioned as a micro-cap player in the global diabetes care market, where demand is driven by the rising prevalence of diabetes and the ongoing shift toward injectable therapies such as insulin pens. Its business model is heavily dependent on third-party reimbursement, including government healthcare programs and private insurers, which is a defining characteristic of medical device suppliers in this sector.
- GLP-1 drug adoption pressures insulin injection demand
- Rising diabetes prevalence drives pen needle volume growth
- Wholesaler pricing power compresses product gross margins
| Net Income: 111.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 16.34 > 1.0 |
| NWC/Revenue: 34.61% < 20% (prev 35.58%; Δ -0.97% < -1%) |
| CFO/TA 0.21 > 3% & CFO 213.5m > Net Income 111.9m |
| Net Debt (1.20b) to EBITDA (322.2m): 3.74 < 3 |
| Current Ratio: 2.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 0.50% < -2% |
| Gross Margin: 62.52% > 18% (prev 63.70%; Δ -1.17% > 0.5%) |
| Asset Turnover: 97.00% > 50% (prev 96.37%; Δ 0.63% > 0%) |
| Interest Coverage Ratio: 2.71 > 6 (EBIT TTM 269.0m / Interest Expense TTM 99.4m) |
| A: 0.35 (Total Current Assets 608.1m - Total Current Liabilities 247.3m) / Total Assets 1.03b |
| B: -0.41 (Retained Earnings -424.7m / Total Assets 1.03b) |
| C: 0.25 (EBIT TTM 269.0m / Avg Total Assets 1.07b) |
| D: -0.38 (Book Value of Equity -626.1m / Total Liabilities 1.66b) |
| Altman-Z'' = 2.24 = BBB |
| DSRI: 0.75 (Receivables 147.1m/202.6m, Revenue 1.04b/1.08b) |
| GMI: 1.02 (GM 63.70% / 62.52%) |
| AQI: 0.91 (AQ_t 0.18 / AQ_t-1 0.20) |
| SGI: 0.97 (Revenue 1.04b / 1.08b) |
| TATA: -0.10 (NI 111.9m - CFO 213.5m) / TA 1.03b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at USD 3.44 with a total of 875,292 shares traded. Over the past week, the price has changed by -0.15%, over one month by +3.78%, over three months by -62.71% and over the past year by -68.42%.
Current recommended Stop Loss: 3.00 (which is 12.8% or 2.7 ATR below the current price).
Embecta has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold EMBC.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 4 | 16.3% |
P/E Trailing = 1.7407
P/S = 0.1872
P/B = 2.6134
Revenue TTM = 1.04b USD
EBIT TTM = 269.0m USD
EBITDA TTM = 322.2m USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 31.3m
Net Debt = 1.20b USD (calculated: Debt 1.39b - CCE 184.9m)
Enterprise Value = 1.40b USD (195.2m + Debt 1.39b - CCE 184.9m)
Interest Coverage Ratio = 2.71 (Ebit TTM 269.0m / Interest Expense TTM 99.4m)
EV/FCF = 6.84x (Enterprise Value 1.40b / FCF TTM 204.7m)
FCF Yield = 14.63% (FCF TTM 204.7m / Enterprise Value 1.40b)
FCF Margin = 19.64% (FCF TTM 204.7m / Revenue TTM 1.04b)
Net Margin = 10.73% (Net Income TTM 111.9m / Revenue TTM 1.04b)
Gross Margin = 62.52% ((Revenue TTM 1.04b - Cost of Revenue TTM 390.7m) / Revenue TTM)
Gross Margin QoQ = 56.45% (prev 67.23%)
Tobins Q-Ratio = 1.36 (Enterprise Value 1.40b / Total Assets 1.03b)
Interest Expense / Debt = 7.16% (Interest Expense 99.4m / Debt 1.39b)
Taxrate = 34.02% (57.7m / 169.6m)
NOPAT = 177.5m (EBIT 269.0m * (1 - 34.02%))
Current Ratio = 2.46 (Total Current Assets 608.1m / Total Current Liabilities 247.3m)
Debt / Equity = -2.22 (negative equity) (Debt 1.39b / totalStockholderEquity, last quarter -626.1m)
Debt / EBITDA = 3.74 (Net Debt 1.20b / EBITDA 322.2m)
Debt / FCF = 5.88 (Net Debt 1.20b / FCF TTM 204.7m)
Total Stockholder Equity = -640.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.41% (Net Income 111.9m / Total Assets 1.03b)
RoE = -17.48% (negative equity) (Net Income TTM 111.9m / Total Stockholder Equity -640.0m)
RoCE = 39.74% (EBIT 269.0m / Capital Employed (Equity -640.0m + L.T.Debt 1.32b))
RoIC = 23.89% (NOPAT 177.5m / Invested Capital 742.9m)
WACC = 5.00% (E(195.2m)/V(1.58b) * Re(7.02%) + D(1.39b)/V(1.58b) * Rd(7.16%) * (1-Tc(0.34)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.13 | Cagr: 0.98%
[DCF] Terminal Value 77.97% ; FCFF base≈138.7m ; Y1≈159.0m ; Y5≈234.0m
[DCF] Fair Price = 39.06 (EV 3.52b - Net Debt 1.20b = Equity 2.32b / Shares 59.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -22.66 | EPS CAGR: -2.73% | SUE: -1.28 | # QB: -1
Revenue Correlation: -82.71 | Revenue CAGR: -2.19% | SUE: -1.57 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=+0.00% | Revisions=-57% | Analysts=4
EPS current Year (2026-09-30): EPS=1.59 | Chg30d=+0.00% | Revisions=-57% | GrowthEPS=-46.0% | GrowthRev=-5.4%
EPS next Year (2027-09-30): EPS=1.74 | Chg30d=+0.00% | Revisions=-57% | GrowthEPS=+9.3% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -80% (up=0, down=12)